{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:28:22Z","timestamp":1787646502948,"version":"build-2736575974"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s12022-026-09932-0","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:32:58Z","timestamp":1787639578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System"],"prefix":"10.1007","volume":"37","author":[{"given":"Anandi","family":"Lobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"9932_CR1","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12022-016-9444-5","volume":"27","author":"E Kouba","year":"2016","unstructured":"Kouba E, Cheng L. Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization Classification: Molecular and clinical characteristics. Endocr Pathol. 2016; 27:188\u201399.","journal-title":"Endocr Pathol"},{"key":"9932_CR2","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Urinary and Male Genital Tumours. 5th ed, Vol 8, Lyon (France): International Agency for Research on Cancer (IARC), 2022."},{"key":"9932_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","volume":"136","author":"SK Mohanty","year":"2023","unstructured":"Mohanty SK, Lobo A, Cheng L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol. 2023; 136:123\u201343.","journal-title":"Hum Pathol"},{"issue":"11","key":"9932_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/jamaoncol.2016.7013","volume":"3","author":"EJ Kouba","year":"2017","unstructured":"Kouba EJ, Cheng L. Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment: A Review. JAMA Oncol. 2017;3(11):1570\u201378.","journal-title":"JAMA Oncol"},{"issue":"1","key":"9932_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115\u201354.","journal-title":"Endocr Pathol"},{"issue":"6","key":"9932_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/PAT.0000000000000301","volume":"47","author":"S Gupta","year":"2015","unstructured":"Gupta S, Thompson RH, Boorjian SA, Thapa P, Hernandez LP, Jimenez RE et al. High-grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology. 2015;47(6):533\u201342.","journal-title":"Pathology"},{"issue":"10","key":"9932_CR7","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/PAS.0000000000001740","volume":"45","author":"G Wang","year":"2021","unstructured":"Wang G, Yuan R, Zhou C, Guo C, Villamil C, Hayes M et al. Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases. Am J Surg Pathol. 2021;45(10):1399\u2013408.","journal-title":"Am J Surg Pathol"},{"key":"9932_CR8","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.5858\/2003-127-e22-CTOTU","volume":"127","author":"G Martignoni","year":"2003","unstructured":"Martignoni G, Eble JN. Carcinoid tumors of the urinary bladder. Immunohistochemical study of 2 cases and review of the literature. Arch Pathol Lab Med. 2003;127: e22\u2013e24.","journal-title":"Arch Pathol Lab Med"},{"key":"9932_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<844::AID-CNCR15>3.0.CO;2-I","volume":"88","author":"L Cheng","year":"2000","unstructured":"Cheng L, Leibovich BC, Cheville JC, et al. Pheochromocytoma of the urinary bladder: Can biologic potential be predicted? Cancer 2000; 88:844\u201352","journal-title":"Cancer"},{"key":"9932_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.anndiagpath.2019.06.009","volume":"42","author":"AN Shehabeldin","year":"2019","unstructured":"Shehabeldin AN, Ro JY. Neuroendocrine tumors of genitourinary tract: Recent advances. Ann Diagn Pathol. 2019; 42:48\u201358.","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"9932_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/his.70044","volume":"88","author":"D Akbulut","year":"2026","unstructured":"Akbulut D, Al-Ahmadie H. Neuroendocrine tumours of the urinary bladder: recent advances. Histopathology. 2026;88(1):108\u201321.","journal-title":"Histopathology"},{"issue":"5","key":"9932_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S0002-9440(10)62369-3","volume":"166","author":"L Cheng","year":"2005","unstructured":"Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166(5):1533\u20139.","journal-title":"Am J Pathol"},{"issue":"1","key":"9932_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1464-410X.2003.04893.x","volume":"94","author":"P Sved","year":"2004","unstructured":"Sved P, Gomez P, Manoharan M, Civantos F, Soloway MS. Small cell carcinoma of the bladder. BJU Int. 2004;94(1):12\u20137.","journal-title":"BJU Int"},{"issue":"8","key":"9932_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.humpath.2007.12.017","volume":"39","author":"NT Gaisa","year":"2008","unstructured":"Gaisa NT, Tilki D, Losen I, Dahl E, Stoehr R, Stief CG et al. Insights from a whole cystectomy specimen\u2013association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. Hum Pathol. 2008;39(8):1258\u201362.","journal-title":"Hum Pathol"},{"issue":"2","key":"9932_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/his.14707","volume":"81","author":"A Gopalan","year":"2022","unstructured":"Gopalan A, Al-Ahmadie H, Chen YB, Sarungbam J, Sirintrapun SJ, Tickoo SK et al. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. Histopathology. 2022;81(2):246\u201354.","journal-title":"Histopathology"},{"issue":"23","key":"9932_CR16","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019;25(23):6916\u201324.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"9932_CR17","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018;36(24):2492\u2013503.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9932_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.17305\/bb.2025.13151","volume":"26","author":"T Zhang","year":"2025","unstructured":"Zhang T, Zhang X, Qian L, Hu C, Li J. Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review. Biomol Biomed. 2025;26(5):711\u201319.","journal-title":"Biomol Biomed"},{"issue":"7457","key":"9932_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499(7457):214\u20138.","journal-title":"Nature"},{"issue":"2","key":"9932_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer 2021;21(2):104\u201321.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"9932_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017;171(3):540\u201356.e25.","journal-title":"Cell"},{"issue":"6","key":"9932_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4341","volume":"23","author":"DS Rickman","year":"2017","unstructured":"Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med 2017;23(6):1\u201310.","journal-title":"Nat Med"},{"issue":"7492","key":"9932_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315\u201322.","journal-title":"Nature"},{"issue":"3","key":"9932_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/annonc\/mdy003","volume":"29","author":"S Venkatesan","year":"2018","unstructured":"Venkatesan S, Rosenthal R, Kanu N, McGranahan N, Bartek J, Quezada SA, et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann Oncol. 2018;29(3):563\u201372.","journal-title":"Ann Oncol"},{"issue":"8","key":"9932_CR25","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","volume":"24","author":"MT Chang","year":"2018","unstructured":"Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res. 2018;24(8):1965\u201373.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"9932_CR26","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.7150\/thno.73235","volume":"12","author":"R Shi","year":"2022","unstructured":"Shi R, Wang X, Wu Y, Xu B, Zhao T, Trapp C, et al. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases. Theranostics 2022;12(9):4181\u201399.","journal-title":"Theranostics"},{"key":"9932_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-014-0047-7","volume":"7","author":"X Zheng","year":"2014","unstructured":"Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT 3rd et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. 2014;7:47.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"9932_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.euf.2017.03.007","volume":"4","author":"DS Priemer","year":"2018","unstructured":"Priemer DS, Wang M, Zhang S, Lopez-Beltran A, Kouba E, Montironi R et al. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. Eur Urol Focus. 2018;4(6):880\u20138.","journal-title":"Eur Urol Focus"},{"issue":"7","key":"9932_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/ijc.29526","volume":"137","author":"I Hosen","year":"2015","unstructured":"Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer 2015;137(7):1621\u20139.","journal-title":"Int J Cancer"},{"issue":"4","key":"9932_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1158\/1541-7786.MCR-16-0003","volume":"14","author":"RJ Bell","year":"2016","unstructured":"Bell RJ, Rube HT, Xavier-Magalhaes A, Costa BM, Mancini A, Song JS et al. Understanding TERT promoter mutations: a common path to immortality. Mol Cancer Res 2016;14(4):315\u201323.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"9932_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","volume":"4","author":"J Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM, et al. Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile. Eur Urol Oncol 2021;4(2):297\u2013300.","journal-title":"Eur Urol Oncol"},{"key":"9932_CR32","doi-asserted-by":"crossref","unstructured":"Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li W, et al. Immune exclusion is frequent in small-cell carcinoma of the bladder. Dis Markers 2019; 2019:2532518.","DOI":"10.1155\/2019\/2532518"},{"key":"9932_CR33","doi-asserted-by":"crossref","unstructured":"Cheng L, Lopez-Beltran A, Montironi R. Bladder Pathology. 2nd edition. Wiley, Hoboken,, NJ; 2025.","DOI":"10.1002\/9781119707677"},{"key":"9932_CR34","volume-title":"Urologic Surgical Pathology","author":"L Cheng","year":"2027","unstructured":"Cheng L, MacLennan GT, Bostwick DG. Urologic Surgical Pathology, 5th ed., Elsevier, Philadelphia, PA, 2027.","edition":"5"},{"issue":"6","key":"9932_CR35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1185\/03007995.2016.1155982","volume":"32","author":"GU Erdem","year":"2016","unstructured":"Erdem GU, \u00d6zdemir NY, Demirci NS, \u015eahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin 2016;32(6):1013\u201321.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"9932_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2559.2004.01980.x","volume":"46","author":"NA Abrahams","year":"2005","unstructured":"Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 2005;46(1):57\u201363.","journal-title":"Histopathology"},{"issue":"9","key":"9932_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2174\/0929867321666131201141346","volume":"21","author":"N Pompas-Veganzones","year":"2014","unstructured":"Pompas-Veganzones N, Gonzalez-Peramato P, Sanchez-Carbayo M. The neuroendocrine component in bladder tumors. Curr Med Chem 2014;21(9):1117\u201328.","journal-title":"Curr Med Chem"},{"issue":"3","key":"9932_CR38","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.juro.2009.11.018","volume":"183","author":"M Ploeg","year":"2010","unstructured":"Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol. 2010;183(3):915\u201320.","journal-title":"J Urol"},{"issue":"2","key":"9932_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/1097-0142(19920115)69:2<527::AID-CNCR2820690241>3.0.CO;2-7","volume":"69","author":"DJ Grignon","year":"1992","unstructured":"Grignon DJ, Ro JY, Ayala AG, Shum DT, Ord\u00f3\u00f1ez NG, Logothetis CJ et al. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer. 1992;69(2):527\u201336.","journal-title":"Cancer"},{"issue":"4","key":"9932_CR40","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.4081\/rt.2015.5982","volume":"7","author":"N Eliyakin","year":"2015","unstructured":"Eliyakin N, Postaci H, Baskin Y, Kozacio\u011flu Z. Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations. Rare Tumors. 2015;7(4):5982.","journal-title":"Rare Tumors"},{"key":"9932_CR41","first-page":"1179","volume":"6","author":"CP Hou","year":"2013","unstructured":"Hou CP, Lin YH, Chen CL, Chang PL, Tsui KH. Clinical outcome of primary small cell carcinoma of the urinary bladder. Onco Targets Ther. 2013; 6:1179\u201385.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"9932_CR42","first-page":"E30-44","volume":"96","author":"N Ismaili","year":"2009","unstructured":"Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay JY, Droz JP et al.Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer. 2009;96(6):E30-44.","journal-title":"Bull Cancer"},{"issue":"6","key":"9932_CR43","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q","volume":"64","author":"CE Blomjous","year":"1989","unstructured":"Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer. 1989;64(6):1347\u201357.","journal-title":"Cancer"},{"issue":"3","key":"9932_CR44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2217\/fon.14.277","volume":"11","author":"K Shatagopam","year":"2015","unstructured":"Shatagopam K, Kaimakliotis HZ, Cheng L, Koch MO. Genitourinary small cell malignancies: prostate and bladder. Future Oncol. 2015;11(3):479\u201388.","journal-title":"Future Oncol"},{"issue":"2","key":"9932_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2013.09.009","volume":"191","author":"SG Patel","year":"2014","unstructured":"Patel SG, Stimson CJ, Zaid HB, Resnick MJ, Cookson MS, Barocas DA et al. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol. 2014;191(2):329\u201334.","journal-title":"J Urol"},{"key":"9932_CR46","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/cncr.20903","volume":"103","author":"NW Choong","year":"2005","unstructured":"Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005;103: 1172\u20138.","journal-title":"Cancer"},{"issue":"4","key":"9932_CR47","doi-asserted-by":"publisher","first-page":"e724-e732","DOI":"10.1016\/j.clgc.2019.03.010","volume":"17","author":"C Cattrini","year":"2019","unstructured":"Cattrini C, Cerbone L, Rubagotti A, Zinoli L, Latocca MM, Messina C et al. Prognostic Variables in Patients with Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study. Clin Genitourin Cancer. 2019;17(4):e724-e732.","journal-title":"Clin Genitourin Cancer"},{"key":"9932_CR48","doi-asserted-by":"crossref","unstructured":"Cheng L, Netto GJ, Eble JN. Molecular Surgical Pathology, 2nd edition. Springer, New York, NY, 2023.","DOI":"10.1007\/978-3-031-35118-1"},{"key":"9932_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.humpath.2018.05.005","volume":"79","author":"G Wang","year":"2018","unstructured":"Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP et al. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018;79:57\u201365.","journal-title":"Hum Pathol"},{"key":"9932_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2162-3619-4-2","volume":"4","author":"X Zheng","year":"2015","unstructured":"Zheng X, Liu D, Fallon JT, Zhong M. Distinct genetic alterations in small cell carcinoma from different anatomic sites. Exp Hematol Oncol. 2015;4:2.","journal-title":"Exp Hematol Oncol"},{"key":"9932_CR51","volume-title":"Essentials of Anatomic Pathology","author":"L Cheng","year":"2027","unstructured":"Cheng L. Essentials of Anatomic Pathology, 5th ed. Springer, New York, NY, 2027.","edition":"5"},{"key":"9932_CR52","volume-title":"Genitourinary Pathology","author":"A Lopez-Beltran","year":"2027","unstructured":"Lopez-Beltran A, Cheng L. Genitourinary Pathology. Elsevier, Philadelphia, PA, 2027."},{"issue":"6","key":"9932_CR53","doi-asserted-by":"publisher","first-page":"152993","DOI":"10.1016\/j.prp.2020.152993","volume":"216","author":"JF Chen","year":"2020","unstructured":"Chen JF, Yang C, Sun Y, Cao D. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56. Pathol Res Pract. 2020;216(6):152993.","journal-title":"Pathol Res Pract"},{"issue":"9","key":"9932_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/PAI.0000000000000824","volume":"28","author":"IE Kim Jr","year":"2020","unstructured":"Kim IE Jr, Amin A, Wang LJ, Cheng L, Perrino CM. Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract. Appl Immunohistochem Mol Morphol. 2020;28(9):687\u201393.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"9932_CR55","first-page":"237","volume":"65","author":"M Per\u00e1n Teruel","year":"2012","unstructured":"Per\u00e1n Teruel M, Gim\u00e9nez Bachs JM, Mart\u00ednez Ruiz J, Fern\u00e1ndez Anguita PJ, Nu\u00f1ez Sarri\u00f3n MA, Pastor Guzm\u00e1n JM et al. Neuroendocrine carcinoma of the urinary bladder. 15-year retrospective analysis. Arch Esp Urol. 2012;65(2):237\u201343.","journal-title":"Arch Esp Urol"},{"issue":"6","key":"9932_CR56","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756\u201367.","journal-title":"Am J Surg Pathol"},{"issue":"S1","key":"9932_CR57","doi-asserted-by":"publisher","first-page":"S122-32","DOI":"10.1038\/modpathol.2017.164","volume":"31","author":"SW Fine","year":"2018","unstructured":"Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018;31(S1): S122-32.","journal-title":"Mod Pathol"},{"key":"9932_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/01.pai.0000213106.12731.d7","volume":"15","author":"MacLennan GT WangX","year":"2007","unstructured":"WangX, MacLennan GT, Lopez-Beltran A, Cheng L. Small cell carcinoma of the urinary bladder\u2014histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. Appl Immunohistochem Mol Morphol 2007; 15:8\u201318.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"9932_CR59","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s00428-004-1041-1","volume":"445","author":"P Soriano","year":"2004","unstructured":"Soriano P, Navarro S, Gil M,Llombart-Bosch A. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch 2004; 445:292\u20137.","journal-title":"Virchows Arch"},{"issue":"5","key":"9932_CR60","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/cncr.20456","volume":"101","author":"L Cheng","year":"2004","unstructured":"Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin Het al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer.2004;101(5):957\u201362.","journal-title":"Cancer"},{"key":"9932_CR61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0046-8177(00)80199-9","volume":"31","author":"AL Byrd-Gloster","year":"2000","unstructured":"Byrd-Gloster AL, Khoor A, Glass LF, Messina JL, Whitsett JA, Livingston SK et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 2000; 31:58\u201362.","journal-title":"Hum Pathol"},{"key":"9932_CR62","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5858\/2001-125-0228-IFTTFA","volume":"125","author":"W Cheuk","year":"2001","unstructured":"Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001; 125:228\u201331.","journal-title":"Arch Pathol Lab Med"},{"key":"9932_CR63","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/cncr.10840","volume":"95","author":"B Helpap","year":"2002","unstructured":"Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002; 95:1415\u201320.","journal-title":"Cancer"},{"issue":"1","key":"9932_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2010.05.026","volume":"42","author":"CC Guo","year":"2011","unstructured":"Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011;42(1):11\u20137.","journal-title":"Hum Pathol"},{"key":"9932_CR65","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/modpathol.2011.56","volume":"24","author":"SR Williamson","year":"2011","unstructured":"Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S et al.ERG-TMPRSS2rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011; 24:1120\u20137.","journal-title":"Mod Pathol"},{"issue":"1","key":"9932_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12022-025-09871-2","volume":"36","author":"A Lobo","year":"2025","unstructured":"Lobo A, Cheng L. Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice. Endocr Pathol. 2025;36(1):28.","journal-title":"Endocr Pathol"},{"key":"9932_CR67","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","volume":"4","author":"J Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM et al. Urothelial cancers with small cell variant histology have confirmed high tumor mutational burden, frequent TP53 and RB mutations, and a unique gene expression profile. Eur Urol Oncol. 2021;4: 297\u2013300.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"9932_CR68","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/PAP.0000000000000433","volume":"31","author":"D Akbulut","year":"2024","unstructured":"Akbulut D, Al-Ahmadie H. Updates on Urinary Bladder Tumors with Neuroendocrine Features. Adv Anat Pathol. 2024;31(3):169\u201377.","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"9932_CR69","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.path.2018.07.011","volume":"11","author":"H Al-Ahmadie","year":"2018","unstructured":"Al-Ahmadie H, Iyer G. Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants. Surg Pathol Clin. 2018;11(4):713\u201323.","journal-title":"Surg Pathol Clin"},{"issue":"5","key":"9932_CR70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17(5):259\u201370.","journal-title":"Nat Rev Urol"},{"key":"9932_CR71","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y,Sj\u00f6dahl G, Robertson AG, Seiler R et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020; 77:420\u201333.","journal-title":"Eur Urol"},{"key":"9932_CR72","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JM Chan","year":"2021","unstructured":"Chan JM, Quintanal-Villalonga \u00c1, Gao VR, Xie Y, Allaj V, Chaudhary O et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021; 39:1479\u20131496.e18.","journal-title":"Cancer Cell"},{"issue":"3, Suppl","key":"9932_CR73","first-page":"S680","volume":"103","author":"DG Akbulut","year":"2023","unstructured":"Akbulut DG, Gamze Ozcan, Basar Yerebakan Merve, et al. The Prognostic significance of stem cell-like marker PLCG2 and novel neuroendocrine markers in bladder neuroendocrine carcinomas. Laboratory Investigation. 2023;103(3, Suppl): S680\u2013S681","journal-title":"Laboratory Investigation"},{"issue":"5","key":"9932_CR74","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clgc.2022.05.005","volume":"20","author":"MY Teo","year":"2022","unstructured":"Teo MY, Guercio BJ, Arora A, Hao X, Regazzi AM, Donahue Tet al. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated with Neoadjuvant Chemotherapy. Clin Genitourin Cancer. 2022;20(5):431\u201341.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"9932_CR75","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ijrobp.2015.03.019","volume":"92","author":"D Pasquier","year":"2015","unstructured":"Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H et al. Small cell carcinoma of the urinary bladder: a retrospective, multicenter Rare Cancer Networkstudyof107 patients. Int J Radiat Oncol Biol Phys. 2015;92(4): 904\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"9932_CR76","doi-asserted-by":"publisher","first-page":"186","DOI":"10.6004\/jnccn.2026.0022","volume":"24","author":"TW Flaig","year":"2026","unstructured":"Flaig TW, Spiess PE, Abern M, An Y, Bangs R, Begovic J, et al. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(5):186\u2013203.","journal-title":"J Natl Compr Canc Netw"},{"key":"9932_CR77","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/j.1442-2042.2008.02168.x","volume":"15","author":"S Akamatsu","year":"2008","unstructured":"Akamatsu S, Kanamaru S, Ishihara M, Sano T, Soeda A, Hashimoto K. Primary large cell neuroendocrine carcinoma of the urinary bladder. Int J Urol. 2008;15: 1080\u20133.","journal-title":"Int J Urol"},{"key":"9932_CR78","first-page":"1016","volume":"11","author":"S Hailemariam","year":"1998","unstructured":"Hailemariam S, Gaspert A, Komminoth P, Tamboli P, Amin M. Primary, pure, large-cell neuroendocrine carcinoma of the urinary bladder. Mod Pathol. 1998; 11:1016\u201320.","journal-title":"Mod Pathol"},{"key":"9932_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1746-1596-8-19","volume":"8","author":"C Colarossi","year":"2013","unstructured":"Colarossi C, Pino P, Giuffrida D, Aiello E, Costanzo R, Martinetti D et al. Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case report. Diagn Pathol. 2013; 8:19.","journal-title":"Diagn Pathol"},{"key":"9932_CR80","first-page":"739","volume":"103","author":"Gandhi Jea","year":"2023","unstructured":"Gandhi Jea. Pathological, clinical and molecular characterization of large cell neuroendocrine carcinoma (LCNEC) of the urinary tract. Laboratory Investigation. 2023; 103:739.","journal-title":"Laboratory Investigation"},{"key":"9932_CR81","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.4081\/rt.2014.5043","volume":"6","author":"VR Bhatt","year":"2014","unstructured":"Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang J. Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors. 2014; 6:5043.","journal-title":"Rare Tumors"},{"key":"9932_CR82","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000356270","volume":"7","author":"HM Coelho","year":"2013","unstructured":"Coelho HM, Pereira BA, Caetano PA. Large cell neuroendocrine carcinoma of the urinary bladder: case report and review. Curr Urol. 2013; 7:155\u2013159.","journal-title":"Curr Urol"},{"key":"9932_CR83","doi-asserted-by":"crossref","unstructured":"Hata S, Tasaki Y. A case of the large cell neuroendocrine carcinoma of the urinary bladder. Case Rep Med. 2013; 2013:804136.","DOI":"10.1155\/2013\/804136"},{"key":"9932_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4322\/acr.2013.028","volume":"3","author":"VF de Vasconcellos","year":"2013","unstructured":"de Vasconcellos VF, Trancoso JLL, Felipe-Silva A, Sim\u00f5es AB, Dos Santos PJ, Fugita OEH et al. Unusual presentation of high-grade neuroendocrine carcinoma of the Urinary bladder with small-cell and large-cell features. Autopsy Case Rep. 2013;3: 67\u201375.","journal-title":"Autopsy Case Rep"},{"key":"9932_CR85","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1078\/0344-0338-00462","volume":"199","author":"P Dundr","year":"2003","unstructured":"Dundr P, Pesl M, Povysil C, Dvor\u00e1cek J. Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features. Pathol Res Pract. 2003; 199:559\u201363.","journal-title":"Pathol Res Pract"},{"key":"9932_CR86","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.5858\/2002-126-1229-PLCNCO","volume":"126","author":"AJ Evans","year":"2002","unstructured":"Evans AJ, Al-Maghrabi J, Tsihlias J, Lajoie G, Sweet JM, Chapman WB. Primary large cell neuroendocrine carcinoma of the urinary bladder. Arch Pathol Lab Med. 2002; 126:1229\u201332.","journal-title":"Arch Pathol Lab Med"},{"key":"9932_CR87","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1440-1827.2006.02031.x","volume":"56","author":"KH Lee","year":"2006","unstructured":"Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C. Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int. 2006; 56:688\u201393.","journal-title":"Pathol Int"},{"key":"9932_CR88","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/DAD.0b013e31818eba4c","volume":"31","author":"WJ Lee","year":"2009","unstructured":"Lee WJ, Kim CH,ChangSE,Lee MW, Choi JH, Moon KCet al. Cutaneous metastasis from large cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. Am J Dermatopathol. 2009; 31:166\u20139.","journal-title":"Am J Dermatopathol"},{"key":"9932_CR89","first-page":"82","volume":"106","author":"T Pusiol","year":"2014","unstructured":"Pusiol T, Morichetti D, Zorzi MG. \u201cPure\u201d primary large cell neuroendocrine carcinoma of the urinary bladder: case report, literature review and diagnostic criteria. Pathologica. 2014; 106:82\u20135.","journal-title":"Pathologica"},{"key":"9932_CR90","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/j.clgc.2015.03.005","volume":"13","author":"N Radovic","year":"2015","unstructured":"Radovic N, Turner R, Bacalja J. Primary \u201cpure\u201d large cell neuro endocrine carcinoma of the urinary bladder: a case report and review of the literature. Clin Genitourin Cancer. 2015;13: e375\u2013e377.","journal-title":"Clin Genitourin Cancer"},{"key":"9932_CR91","first-page":"138","volume":"29","author":"A Sari","year":"2013","unstructured":"Sari A, Ermete M, Sadullahoglu C, Bal K, Bol\u00fckba\u015fi A. Large cell neuroendocrine carcinoma of urinary bladder; case presentation. Turk Patoloji Derg. 2013; 29:138\u201342.","journal-title":"Turk Patoloji Derg"},{"key":"9932_CR92","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/j.1464-410X.2009.08451.x","volume":"103","author":"R Mazzucchelli","year":"2009","unstructured":"Mazzucchelli R, Morichetti D, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z et al. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int. 2009; 103:1464\u201370.","journal-title":"BJU Int"},{"issue":"1","key":"9932_CR93","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/his.13719","volume":"74","author":"S Park","year":"2019","unstructured":"Park S, Reuter VE, Hansel DE. Non-urothelial carcinomas of the bladder. Histopathology. 2019;74(1):97\u2013111.","journal-title":"Histopathology"},{"key":"9932_CR94","first-page":"105","volume":"64","author":"IJ Martin","year":"2011","unstructured":"Martin IJ, Vilar DG, Aguado JM, Perell\u00f3 CG, Aliaga MR, Argente VG et al. Large cell neuroendocrine carcinoma of the urinary bladder. Bibliographic review. Arch Esp Urol 2011; 64:105\u201313.","journal-title":"Arch Esp Urol"},{"key":"9932_CR95","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/PAI.0b013e31820eca9a","volume":"19","author":"S Thompson","year":"2011","unstructured":"Thompson S, Cioffi-Lavina M, Chapman-Fredricks J, Gomez-Fernandez C, Fernandez-Castro G, Jorda M. Distinction of high-grade neuroendocrine carcinoma\/small cell carcinoma from conventional urothelial carcinoma of urinary bladder: an immunohistochemical approach. Appl Immunohistochem Mol Morphol. 2011; 19:395\u201399.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"15_suppl","key":"9932_CR96","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1200\/JCO.2021.39.15_suppl.4526","volume":"39","author":"BJ Guercio","year":"2021","unstructured":"Guercio BJ, Gandhi J, Teo MY, Lattanzi M, Funt SA, Aggen DH et al. Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): the MSKCC experience. Journal of Clinical Oncology. 2021;39 (15_suppl):4526\u20134526.","journal-title":"Journal of Clinical Oncology"},{"key":"9932_CR97","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1440-1827.2006.02031.x","volume":"56","author":"KH Lee","year":"2006","unstructured":"Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C. Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int 2006; 56:688\u201393.","journal-title":"Pathol Int"},{"key":"9932_CR98","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/2152-7806.82250","volume":"2","author":"A Tsugu","year":"2011","unstructured":"Tsugu A, Yoshiyama M, Matsumae M. Brain metastasis from large cell neuroendocrine carcinoma of the urinary bladder. Surg Neurol Int 2011; 2:84.","journal-title":"Surg Neurol Int"},{"key":"9932_CR99","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2016.03.006","volume":"95","author":"B MetroG,Ricciuti","year":"2016","unstructured":"MetroG,Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D et al. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer 2016; 95:82\u20137.","journal-title":"Lung Cancer"},{"key":"9932_CR100","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/DAD.0b013e31818eba4c","volume":"31","author":"WJ Lee","year":"2009","unstructured":"Lee WJ, Kim CH, Chang SE, Lee MW, Choi JH, Moon KCet al. Cutaneous metastasis from large-cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. Am J Dermatopathol 2009; 31:166\u20139.","journal-title":"Am J Dermatopathol"},{"key":"9932_CR101","first-page":"105","volume":"64","author":"IJ Martin","year":"2011","unstructured":"Martin IJ, Vilar DG, Aguado JM, Perell\u00f3 CG, Aliaga MR, Argente VGet al. Large cell neuroendocrine carcinoma of the urinary bladder. Bibliographic review. Arch Esp Urol. 2011; 64:105\u201313.","journal-title":"Arch Esp Urol"},{"key":"9932_CR102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.ju.0000162085.20043.1f","volume":"174","author":"ML Quek","year":"2005","unstructured":"Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience. J Urol. 2005; 174:93\u20136.","journal-title":"J Urol"},{"key":"9932_CR103","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.21873\/anticanres.14213","volume":"40","author":"F Sanguedolce","year":"2020","unstructured":"Sanguedolce F, Calo B, Chirico M, Tortorella S, Carrieri G, Cormio L. Urinary tract large cell neuroendocrine carcinoma: diagnostic, prognostic and therapeutic issues. Anticancer Res. 2020; 40:2439\u201347.","journal-title":"Anticancer Res"},{"key":"9932_CR104","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3389\/fonc.2020.01291","volume":"10","author":"K Xia","year":"2020","unstructured":"Xia K, Zhong W, Chen J, Lai Y, Huang G, Liu H et al. Clinical Characteristics, Treatment Strategy, and Outcomes of Primary Large Cell Neuroendocrine Carcinoma of the Bladder: A Case Report and Systematic Review of the Literature. Front Oncol. 2020; 10:1291.","journal-title":"Front Oncol"},{"issue":"6","key":"9932_CR105","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.21873\/anticanres.12589","volume":"38","author":"B P\u00f3sfai","year":"2018","unstructured":"P\u00f3sfai B, Kuthi L, Varga L, Lacz\u00f3 I, R\u00e9v\u00e9sz J, Kr\u00e1nicz R et al. The colorful palette of neuroendocrine neoplasms in the genitourinary tract. Anticancer Res 2018;38(6):3243\u201354.","journal-title":"Anticancer Res"},{"key":"9932_CR106","first-page":"199","volume":"104","author":"TV Colby","year":"1980","unstructured":"Colby TV. Carcinoid tumor of the bladder. A case report. Arch Pathol Lab Med 1980; 104:199\u2013200.","journal-title":"Arch Pathol Lab Med"},{"key":"9932_CR107","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/PAS.0b013e318208f96a","volume":"35","author":"YB Chen","year":"2011","unstructured":"Chen YB, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol2011; 35:442\u20136.","journal-title":"Am J Surg Pathol"},{"key":"9932_CR108","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","volume":"33","author":"PL Kunz","year":"2015","unstructured":"Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 2015; 33:1855\u201363.","journal-title":"J Clin Oncol"},{"key":"9932_CR109","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.prp.2011.10.008","volume":"208","author":"M Zozumi","year":"2012","unstructured":"Zozumi M, Nakai M, Matsuda I, Hao H, Ueda Y, Nojima M, et al. Primary carcinoid tumor of the urinary bladder with prominent subnuclear eosinophilic granules. Pathol Res Pract2012; 208:109\u201312.","journal-title":"Pathol Res Pract"},{"key":"9932_CR110","first-page":"446","volume":"58","author":"JE McCabe","year":"2005","unstructured":"McCabe JE, Das S, Dowling P, Hamid BN, Pettersson BA. Oncocytic carcinoid tumour of the bladder. J Clin Pathol2005; 58:446\u20137.","journal-title":"J Clin Pathol"},{"key":"9932_CR111","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1023\/A:1014400818905","volume":"33","author":"A Sugihara","year":"2002","unstructured":"Sugihara A, Kajio K, Yoshimoto T, Tsujimura T, Iwasaki T, Yamada N, et al. Primary carcinoid tumor of the urinary bladder. Int Urol Nephrol 2002; 33:53\u20137.","journal-title":"Int Urol Nephrol"},{"key":"9932_CR112","first-page":"666","volume":"118","author":"BL Stanfield","year":"1994","unstructured":"Stanfield BL, Grimes MM, Kay S. Primary carcinoid tumor of the bladder arising beneath an inverted papilloma. Arch Pathol Lab Med 1994; 118:666\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"9932_CR113","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/PAS.0b013e31823455eb","volume":"35","author":"DE Baydar","year":"2011","unstructured":"Baydar DE, Tasar C. Carcinoid tumor in the urinary bladder: unreported features. Am J Surg Pathol 2011; 35:1754\u20137.","journal-title":"Am J Surg Pathol"},{"key":"9932_CR114","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.5858\/2006-130-1693-CTOTUT","volume":"130","author":"R Murali","year":"2006","unstructured":"Murali R, Kneale K, Lalak N, Delprado W. Carcinoid tumors of the urinary tract and prostate. Arch Pathol Lab Med 2006;130: 1693\u2013706.","journal-title":"Arch Pathol Lab Med"},{"key":"9932_CR115","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2407-5-88","volume":"5","author":"M Mascolo","year":"2005","unstructured":"Mascolo M, Altieri V, Mignogna C, Napodano G, De Rosa G, Insabato L. Calcitonin-producing well-differentiated neuroendocrine carcinoma (carcinoid tumor) of the urinary bladder: case report. BMC Cancer 2005; 5:88.","journal-title":"BMC Cancer"},{"key":"9932_CR116","first-page":"1217","volume":"116","author":"BF Walker","year":"1992","unstructured":"Walker BF, Someren A, Kennedy JC, Nicholas EM. Primary carcinoid tumor of the urinary bladder. Arch Pathol Lab Med 1992; 116:1217\u201320.","journal-title":"Arch Pathol Lab Med"},{"key":"9932_CR117","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0090-4295(92)90484-E","volume":"40","author":"NW Chin","year":"1992","unstructured":"Chin NW, Marinescu AM, Fani K. Composite adenocarcinoma and carcinoid tumor of urinary bladder. Urology 1992; 40:249\u201352.","journal-title":"Urology"},{"key":"9932_CR118","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0090-4295(00)00470-2","volume":"55","author":"AK Hemal","year":"2000","unstructured":"Hemal AK, Singh I, Pawar R, Kumar M, Taneja P. Primary malignant bladder carcinoid\u2013a diagnostic and management dilemma. Urology 2000; 55:949.","journal-title":"Urology"},{"issue":"4","key":"9932_CR119","first-page":"9421","volume":"25","author":"J Warncke","year":"2018","unstructured":"Warncke J, White S, O\u2019Keefe M, Kim F, da Silva RD. Primary carcinoid tumor of the bladder. Can J Urol. 2018;25(4):9421\u20133.","journal-title":"Can J Urol"},{"issue":"11","key":"9932_CR120","first-page":"445","volume":"61","author":"N Ueda","year":"2015","unstructured":"Ueda N, Arai H, Honda M, Yoshida K. Primary Carcinoid Tumor of the Urinary Bladder: A Case Report and Questionnaire Survey on the Reported Cases in Japan. Hinyokika Kiyo. 2015;61(11):445\u20138.","journal-title":"Hinyokika Kiyo"},{"issue":"2","key":"9932_CR121","first-page":"53","volume":"68","author":"K Kano","year":"2022","unstructured":"Kano K, Ishiyama R, Yagisawa T, Odani K, Kanemitsu I, Kobayashi H et al. Primary Carcinoid Tumor of the Urinary Bladder: A Case Report. Hinyokika Kiyo. 2022;68(2):53\u20137.","journal-title":"Hinyokika Kiyo"},{"key":"9932_CR122","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.humpath.2020.11.014","volume":"109","author":"MDC Rodriguez Pena","year":"2021","unstructured":"Rodriguez Pena MDC, Salles DC, Epstein JI, Canete-Portillo S, Tregnago AC, Ramirez Jet al. Well-differentiated neuroendocrine tumors of the lower urinary tract: Biologic behavior of a rare entity. Hum Pathol. 2021; 109:53\u201358.","journal-title":"Hum Pathol"},{"issue":"4","key":"9932_CR123","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12022-016-9432-9","volume":"27","author":"S La Rosa","year":"2016","unstructured":"La Rosa S, Sessa F, Uccella S. Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms. Endocr Pathol. 2016;27(4):284\u2013311.","journal-title":"Endocr Pathol"},{"issue":"1","key":"9932_CR124","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00428-021-03023-7","volume":"479","author":"GM Pini","year":"2021","unstructured":"Pini GM, Uccella S, Corinti M, Colecchia M, Pelosi G, Patriarca C. Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior: Description of a case and review of the pertinent literature. Virchows Arch. 2021;479(1):69\u201378.","journal-title":"Virchows Arch"},{"issue":"10","key":"9932_CR125","doi-asserted-by":"publisher","first-page":"rjae612","DOI":"10.1093\/jscr\/rjae612","volume":"2024","author":"P Tran","year":"2024","unstructured":"Tran P, Rama Sai P, Prasad C, Do H, Parsa C. Mixed neuroendocrine-nonneuroendocrine epithelial neoplasm of muscle invasive bladder cancer: a clinicopathologic case study. J Surg Case Rep. 2024;2024(10): rjae612.","journal-title":"J Surg Case Rep"},{"issue":"2","key":"9932_CR126","first-page":"53","volume":"14","author":"B Masood","year":"2020","unstructured":"Masood B, Iqbal N, Iqbal W, Masood Y, Akbar MK, Mamoon N. Small-cell neuroendocrine carcinoma of the urinary bladder: A case report. Int J Health Sci (Qassim). 2020;14(2):53\u20135.","journal-title":"Int J Health Sci (Qassim)"},{"issue":"9","key":"9932_CR127","doi-asserted-by":"publisher","first-page":"e9444","DOI":"10.1002\/ccr3.9444","volume":"12","author":"MSEK Salem","year":"2024","unstructured":"Salem MSEK, Alherek A, Van Rooyen M, Mukendi AM. Unusual coexistence: A case of mixed small and large cell neuroendocrine tumor in a bladder previously affected by bilharzial cystitis. Clin Case Rep. 2024;12(9): e9444.","journal-title":"Clin Case Rep"},{"issue":"1","key":"9932_CR128","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/JU.0000000000001325","volume":"205","author":"A Hajiran","year":"2021","unstructured":"Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon Jet al. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021;205(1):100\u20138.","journal-title":"J Urol"},{"issue":"7","key":"9932_CR129","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.urolonc.2017.02.006","volume":"35","author":"S Purnell","year":"2017","unstructured":"Purnell S, Sidana A, Maruf M, Grant C, Agarwal PK. Genitourinary paraganglioma: Demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000\u20132012). Urol Oncol. 2017;35(7):457. e9-457.e14.","journal-title":"Urol Oncol"},{"key":"9932_CR130","doi-asserted-by":"crossref","unstructured":"Martucci VL, Lorenzo ZG, Weintraub M, Ling A, Merino M, Siddiqui M, et al. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol. 2015;33(4):167. e13-167.e1.67E20.","DOI":"10.1016\/j.urolonc.2014.11.017"},{"issue":"10","key":"9932_CR131","doi-asserted-by":"publisher","first-page":"591","DOI":"10.12998\/wjcc.v2.i10.591","volume":"2","author":"M Ranaweera","year":"2014","unstructured":"Ranaweera M, Chung E. Bladder paraganglioma: a report of case series and critical review of current literature. World J Clin Cases 2014;2(10):591\u20135.","journal-title":"World J Clin Cases"},{"issue":"12","key":"9932_CR132","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","volume":"23","author":"SP Rednam","year":"2017","unstructured":"Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK et al. Von Hippel-Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23(12):e68\u201375.","journal-title":"Clin Cancer Res"},{"key":"9932_CR133","first-page":"99","volume":"70","author":"M Raygada","year":"2011","unstructured":"Raygada M, Pasini B, Stratakis CA. Hereditary paragangliomas. Adv Otorhinolaryngol 2011; 70:99\u2013106.","journal-title":"Adv Otorhinolaryngol"},{"issue":"3","key":"9932_CR134","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11701-016-0573-0","volume":"10","author":"K Bishnoi","year":"2016","unstructured":"Bishnoi K, Bora GS, Mavuduru RS, Devana SK, Singh SK, Mandal AK. Bladder paraganglioma: safe and feasible management with robot assisted surgery. J Robot Surg 2016;10(3):275\u20138.","journal-title":"J Robot Surg"},{"issue":"30","key":"9932_CR135","doi-asserted-by":"publisher","first-page":"e10904","DOI":"10.1097\/MD.0000000000010904","volume":"97","author":"A Stigliano","year":"2018","unstructured":"Stigliano A, Lardo P, Cerquetti L, Aschelter AM, Matarazzo I, Capriotti Get al. Treatment responses to antiangiogenetic therapy and chemotherapy in non-secreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: a case report. Medicine (Baltimore) 2018;97(30): e10904.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"9932_CR136","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4293\/108680810X12785289145042","volume":"14","author":"R Nayyar","year":"2010","unstructured":"Nayyar R, Singh P, Gupta NP. Robotic management of pheochromocytoma of the vesicoureteric junction. JSLS 2010;14(2):309\u201312.","journal-title":"JSLS"},{"issue":"3","key":"9932_CR137","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/RUQ.0000000000000113","volume":"30","author":"D Adraktas","year":"2014","unstructured":"Adraktas D, Caserta M, Tchelepi H. Paraganglioma of the urinary bladder. Ultrasound Q 2014;30(3):233\u20135.","journal-title":"Ultrasound Q"},{"issue":"3","key":"9932_CR138","doi-asserted-by":"publisher","first-page":"e217-20","DOI":"10.1016\/j.ejrad.2010.09.020","volume":"80","author":"H Wang","year":"2011","unstructured":"Wang H, Ye H, Guo A, Wei Z, Zhang X, Zhong Y et al. Bladder paraganglioma in adults: MR appearance in four patients. Eur J Radiol. 2011;80(3): e217-20.","journal-title":"Eur J Radiol"},{"key":"9932_CR139","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","volume":"51","author":"AMA Berends","year":"2018","unstructured":"Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018; 51:68\u201373.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"9932_CR140","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3803\/EnM.2020.35.1.157","volume":"35","author":"JH Kim","year":"2020","unstructured":"Kim JH, Moon H, Noh J, Lee J, Kim SG. Epidemiology and Prognosis of Pheochromocytoma\/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service. Endocrinol Metab (Seoul). 2020;35(1):157\u201364.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"9932_CR141","first-page":"163","volume":"66","author":"MH Kappers","year":"2008","unstructured":"Kappers MH, van den Meiracker AH, Alwani RA, Kats E, Baggen MG. Paraganglioma of the urinary bladder. Neth J Med 2008; 66:163\u20135.","journal-title":"Neth J Med"},{"key":"9932_CR142","first-page":"e25-9","volume":"85","author":"HendersonSJ,KearnsPJ","year":"2015","unstructured":"HendersonSJ,KearnsPJ,TongCM,ReddyM,KhurginJ,BickellM,etal. Patients with urinary bladder paragangliomas: a compiled case series from a literature review for clinical management. Urology 2015;85: e25-9.","journal-title":"Urology"},{"key":"9932_CR143","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2490-13-22","volume":"13","author":"JA Beilan","year":"2013","unstructured":"Beilan JA, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol2013; 13:22.","journal-title":"BMC Urol"},{"issue":"1","key":"9932_CR144","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0377-4929.130873","volume":"57","author":"S Menon","year":"2014","unstructured":"Menon S, Goyal P, Suryawanshi P, Tongaonkar H, Joshi A, Bakshi G et al. Paraganglioma of the urinary bladder: a clinicopathologic spectrum of a series of 14 cases emphasizing diagnostic dilemmas. Indian J Pathol Microbiol. 2014;57(1):19\u201323.","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"9932_CR145","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","volume":"38","author":"M Miettinen","year":"2014","unstructured":"Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13\u201322.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"9932_CR146","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/PAS.0b013e318289c765","volume":"37","author":"D Nonaka","year":"2013","unstructured":"Nonaka D, Wang BY, Edmondson D, Beckett E, Sun CC. A study of GATA3 and PHOX2b expression in tumors of the autonomic nervous system. Am J Surg Pathol. 2013;37(8):1236\u201341.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"9932_CR147","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/modpathol.2013.76","volume":"26","author":"JS So","year":"2013","unstructured":"So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol 2013;26(10):1365\u201370.","journal-title":"Mod Pathol"},{"issue":"1","key":"9932_CR148","first-page":"63","volume":"62","author":"AU Ghafoor","year":"2012","unstructured":"Ghafoor AU, Yousaf I, Pervez R, Khan RU, Mir K. Paraganglioma of urinary bladder: an unusual presentation. pitfalls in diagnosis and treatment. J Pak Med Assoc. 2012;62(1):63\u20135.","journal-title":"J Pak Med Assoc"},{"issue":"11","key":"9932_CR149","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/0046-8177(91)90271-P","volume":"22","author":"DJ Grignon","year":"1991","unstructured":"Grignon DJ, Ro JY, Mackay B, Ord\u00f3\u00f1ez NG, el-Naggar A, Molina TJ et al. Paraganglioma of the urinary bladder: immunohistochemical, ultrastructural, and DNA flow cytometric studies. Hum Pathol. 1991;22(11):1162\u20139.","journal-title":"Hum Pathol"},{"issue":"5","key":"9932_CR150","doi-asserted-by":"publisher","first-page":"671","DOI":"10.5858\/arpa.2016-0403-OA","volume":"141","author":"S Park","year":"2017","unstructured":"Park S, Kang SY, Kwon GY, Kwon JE, Kim SK, Kim JY et al. Clinicopathologic Characteristics and Mutational Status of Succinate Dehydrogenase Genes in Paraganglioma of the Urinary Bladder: A Multi-Institutional Korean Study. Arch Pathol Lab Med. 2017;141(5):671\u20137.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"9932_CR151","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90\u2013114.","journal-title":"Endocr Pathol"},{"issue":"11","key":"9932_CR152","doi-asserted-by":"publisher","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"JM Koh","year":"2017","unstructured":"Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH et al. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One. 2017;12(11): e0187398.","journal-title":"PLoS One"},{"issue":"1","key":"9932_CR153","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00428-025-04379-w","volume":"488","author":"O Mete","year":"2026","unstructured":"Mete O, Juhlin CC. The evolving roles of pathologists in paragangliomas and pheochromocytomas. Virchows Arch. 2026;488(1):173\u201391.","journal-title":"Virchows Arch"},{"issue":"7","key":"9932_CR154","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/PAS.0000000000002238","volume":"48","author":"Q Li","year":"2024","unstructured":"Li Q, Lan Z, Jiang Y, Wang R, Li Z, Jiang X. Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma. Am J Surg Pathol. 2024;48(7):855\u201365.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"9932_CR155","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017;31(2):181\u201393.","journal-title":"Cancer Cell"},{"issue":"2","key":"9932_CR156","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","volume":"25","author":"S Job","year":"2019","unstructured":"Job S, Draskovic I, Burnichon N, Buffet A, Cros J, L\u00e9pine C et al. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2019;25(2):760\u201370.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9932_CR157","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.ju.0000162085.20043.1f","volume":"174","author":"ML Quek","year":"2005","unstructured":"Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience. J Urol 2005;174(1):93\u20136.","journal-title":"J Urol"},{"issue":"2","key":"9932_CR158","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/01.ju.0000132413.85866.fc","volume":"172","author":"AO Siefker-Radtke","year":"2004","unstructured":"Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson cancer experience. J Urol 2004;172(2):481\u20134.","journal-title":"J Urol"},{"issue":"16","key":"9932_CR159","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.2008.19.0256","volume":"27","author":"AO Siefker-Radtke","year":"2009","unstructured":"Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide\/doxorubicin and etoposide\/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009;27(16):2592\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9932_CR160","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.eururo.2012.04.020","volume":"64","author":"SP Lynch","year":"2013","unstructured":"Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013;64(2):307\u201313.","journal-title":"Eur Urol"},{"issue":"22","key":"9932_CR161","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1002\/cncr.30907","volume":"123","author":"MW Vetterlein","year":"2017","unstructured":"Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Loppenberg B, Chun FK et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer2017;123(22):4346\u201355.","journal-title":"Cancer"},{"issue":"6","key":"9932_CR162","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.euo.2023.09.004","volume":"6","author":"O Akbui","year":"2023","unstructured":"Akbui O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ et al. Comparative effectiveness analysis of treatment strategies for surgically resectable neuroendocrine carcinoma of the urinary tract. Eur Urol Oncol 2023;6(6):611\u201320.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"9932_CR163","doi-asserted-by":"publisher","first-page":"102208","DOI":"10.1016\/j.clgc.2024.102208","volume":"22","author":"DR Bakaloudi","year":"2024","unstructured":"Bakaloudi DR, Koehne EL, Diamantopoulos LN, Holt SK, Sekar RR, Ghali F et al. Small cell bladder cancer: treatment patterns for local disease and associated outcomes. a retrospective cohort study. Clin Genitourin Cancer 2024;22(6):102208.","journal-title":"Clin Genitourin Cancer"},{"key":"9932_CR164","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-6-75","volume":"6","author":"N Ismaili","year":"2011","unstructured":"Ismaili N. A rare bladder cancer\u2013small cell carcinoma: review and update. Orphanet J Rare Dis 2011;6:75.","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"9932_CR165","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/1078-0432.CCR-24-1277","volume":"30","author":"J Zang","year":"2024","unstructured":"Zang J, Shahatiaili A, Cai MC, Jin D, Shen P, Qian L et al. Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer. Clin Cancer Res. 2024;30(21):4920\u201331.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9932_CR166","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2023.05.023","volume":"85","author":"M Feng","year":"2024","unstructured":"Feng M, Matoso A, Epstein G, Fong M, Park YH, Gabrielson A et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. 2024;85(6):523\u201326.","journal-title":"Eur Urol"},{"issue":"2","key":"9932_CR167","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.euo.2019.12.002","volume":"4","author":"J Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM et al. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. Eur Urol Oncol. 2021;4(2):297\u2013300.","journal-title":"Eur Urol Oncol"},{"key":"9932_CR168","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.xcrm.2026.102712","volume":"31","author":"Z Chen","year":"2026","unstructured":"Chen Z, Peng S, Fu S, et al. Targeting TPX2-dependent lineage plasticity by CDK4\/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma.Cell Rep Med. 2026; 31:102712.","journal-title":"Cell Rep Med"},{"issue":"12","key":"9932_CR169","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"29","key":"9932_CR170","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37(29):2592\u2013600.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9932_CR171","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","volume":"35","author":"Y Loriot","year":"2024","unstructured":"Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Fl\u00e9chon A, Jain RK, Gupta S et al. TROPHY-U-01, a phase II open-label study of Sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Ann Oncol. 2024;35(4):392\u2013401.","journal-title":"Ann Oncol"},{"issue":"7","key":"9932_CR172","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/PAS.0000000000001264","volume":"43","author":"H Reis","year":"2019","unstructured":"Reis H, Serrette R, Posada J, Lu V, Chen YB, Gopalan A et al. PD-L1 Expression in Urothelial Carcinoma with Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. Am J Surg Pathol. 2019;43(7):920\u20137.","journal-title":"Am J Surg Pathol"},{"key":"9932_CR173","doi-asserted-by":"crossref","unstructured":"Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li W et al. Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Dis Markers. 2019:2532518.","DOI":"10.1155\/2019\/2532518"},{"issue":"3","key":"9932_CR174","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/cam4.3699","volume":"10","author":"M Sarfaty","year":"2021","unstructured":"Sarfaty M, Whiting K, Teo MY, Lee CH, Peters V, Durocher J et al. A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. Cancer Med. 2021;10(3):1074\u201383.","journal-title":"Cancer Med"},{"key":"9932_CR175","doi-asserted-by":"crossref","unstructured":"Gupta S, Vanderbilt CM, Zhang Y, Tickoo SK, Fine SW, Gopalan A et al. CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder Cancer. 2021;7(4):395\u2013400.","DOI":"10.3233\/BLC-201532"},{"issue":"6","key":"9932_CR176","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cncr.33328","volume":"127","author":"BA McGregor","year":"2021","unstructured":"McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021;127(6):840\u20139.","journal-title":"Cancer"},{"issue":"8","key":"9932_CR177","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","volume":"29","author":"JH Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM et al. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. Appl Immunohistochem Mol Morphol. 2021;29(8):619\u201325.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"9932_CR178","doi-asserted-by":"publisher","first-page":"858865","DOI":"10.3389\/fonc.2022.858865","volume":"12","author":"Y Fan","year":"2022","unstructured":"Fan Y, Li Q, Shen Q, Liu Z, Zhang Z, Hu S et al. Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants. Front Oncol. 2022; 12:858865.","journal-title":"Front Oncol"},{"issue":"1","key":"9932_CR179","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/1078-0432.CCR-18-1278","volume":"25","author":"VS Koshkin","year":"2019","unstructured":"Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019;25(1):210\u201321.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9932_CR180","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","volume":"27","author":"J Yao","year":"2022","unstructured":"Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS et al. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022;27(11):940\u201351.","journal-title":"Oncologist"},{"issue":"22","key":"9932_CR181","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M et al; DeLLphi-301 Investigators. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023;389(22):2063\u201375.","journal-title":"N Engl J Med"},{"issue":"4","key":"9932_CR182","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M et al; DeLLphi-304 Investigators. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N Engl J Med. 2025;393(4):349\u201361.","journal-title":"N Engl J Med"},{"issue":"5","key":"9932_CR183","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P et al.AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021;27(5):1526\u201337.","journal-title":"Clin Cancer Res"},{"key":"9932_CR184","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","volume":"1847","author":"F Rojo","year":"2020","unstructured":"Rojo F, Corassa M, Mavroudis D, \u00d6z AB, Biesma B, Brcic L et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020; 1847:237\u201343.","journal-title":"Lung Cancer"},{"issue":"16","key":"9932_CR185","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023;41(16):2893\u2013903.","journal-title":"J Clin Oncol"},{"issue":"6627","key":"9932_CR186","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/386852a0","volume":"386","author":"M Borges","year":"1997","unstructured":"Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997;386(6627):852\u20135.","journal-title":"Nature"},{"issue":"30","key":"9932_CR187","doi-asserted-by":"publisher","first-page":"21160","DOI":"10.1074\/jbc.M708692200","volume":"283","author":"ER Neptune","year":"2008","unstructured":"Neptune ER, Podowski M, Calvi C, Cho JH, Garcia JG, Tuder R et al. Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung. J Biol Chem. 2008;283(30):21160\u20139.","journal-title":"J Biol Chem"},{"issue":"13\u201314","key":"9932_CR188","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","volume":"32","author":"YH Huang","year":"2018","unstructured":"Huang YH, Klingbeil O, He XY, Wu XS, Arun G, Lu B et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018;32(13\u201314):915\u201328.","journal-title":"Genes Dev"},{"issue":"5","key":"9932_CR189","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289\u201397.","journal-title":"Nat Rev Cancer"},{"key":"9932_CR190","doi-asserted-by":"crossref","unstructured":"Akbulut D, Whiting K, Teo MY, Tallman JE, Ozcan GG, Basar M et al. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell\/Neuroendocrine Carcinoma with Prognostic Implications. Mod Pathol. 2024;37(10):100557.","DOI":"10.1016\/j.modpat.2024.100557"},{"issue":"12","key":"9932_CR191","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y et al. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol. 2020;15(12):1823\u201335.","journal-title":"J Thorac Oncol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-026-09932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-026-09932-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-026-09932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:02:30Z","timestamp":1787644950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-026-09932-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":191,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9932"],"URL":"https:\/\/doi.org\/10.1007\/s12022-026-09932-0","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"36"}}